Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab vs Tofacitinib in Moderate to Severe HS
NCT06707246Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Dec 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of secukinumab and tofacitinib oral solution in hidradenitis suppurativa (HS) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Hidradenitis Suppurativa Clinical Response at 12 weeks. Started Dec 2024; status: recruiting.
02
Drugs
secukinumabtofacitinib oral solution
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06707246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06707246.